Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
NCT ID: NCT06830759
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
700 participants
OBSERVATIONAL
2025-03-28
2031-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.
Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Epcoritamab
Participants will receive epcoritamab as prescribed by their physician according to local label.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
* The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.
Exclusion Criteria
* Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genmab
INDUSTRY
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Britanico de Buenos Aires /ID# 274419
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Hospital Universitario Austral /ID# 274393
Pilar, Buenos Aires, Argentina
Instituto Alexander Fleming /ID# 277284
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina
Hospital Privado Universitario De Córdoba /ID# 274457
Córdoba, Córdoba Province, Argentina
Hospital Italiano de Buenos Aires /ID# 274418
Buenos Aires, , Argentina
Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390
Buenos Aires, , Argentina
Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288
Graz, Styria, Austria
Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 273266
Leoben, Styria, Austria
Algemeen Ziekenhuis klina /ID# 273405
Brasschaat, Antwerpen, Belgium
Universitair Ziekenhuis Brussel /ID# 273403
Jette, Brussels Capital, Belgium
Centre Hospitalier Epicura - Hornu /ID# 273406
Boussu, Hainaut, Belgium
Grand Hôpital De Charleroi - Notre Dame /ID# 273728
Charleroi, Hainaut, Belgium
Helora /ID# 273726
La Louvière, Hainaut, Belgium
Groupe Sante CHC - Clinique du MontLegia /ID# 273407
Liège, Liege, Belgium
Ziekenhuis Oost-Limburg, Campus St.-Jan /ID# 273729
Genk, Limburg, Belgium
Vitaz /Id# 273408
Sint-Niklaas, Oost-Vlaanderen, Belgium
AZ Oostende /ID# 273714
Ostend, West-Vlaanderen, Belgium
Umhat Sveti Ivan Rilsky /ID# 274898
Sofiya, Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 274893
Pleven, , Bulgaria
Acibadem City Clinic Tokuda University Hospital EAD /ID# 273659
Sofia, , Bulgaria
Specialized Hospital For Active Treatment Of Haematology Diseases /ID# 274955
Sofia, , Bulgaria
Cross Cancer Institute /ID# 271504
Edmonton, Alberta, Canada
The Moncton Hospital /ID# 277230
Moncton, New Brunswick, Canada
Eastern Health - General Hospital /ID# 272062
St. John's, Newfoundland and Labrador, Canada
Health Sciences North /ID# 274738
Greater Sudbury, Ontario, Canada
Kingston General Hospital /ID# 272061
Kingston, Ontario, Canada
Agios Andreas Hospital Patras /ID# 273629
Pátrai, Achaia, Greece
Evangelismos Hospital /ID# 272736
Athens, Attica, Greece
General Hospital of Athens Laiko /ID# 272758
Athens, Attica, Greece
University General Hospital Attikon /ID# 272738
Athens, Attica, Greece
Metaxa Cancer Hospital Of Piraeus /ID# 273623
Piraeus, Attica, Greece
University General Hospital of Alexandroupoli /ID# 272737
Alexandroupoli, Evros, Greece
University Hospital of Ioannina /ID# 272739
Ioannina, , Greece
AHEPA University General Hospital of Thessaloniki /ID# 273633
Thessaloniki, , Greece
General Hospital of Thessaloniki Hippokrateio /ID# 273635
Thessaloniki, , Greece
Papageorgiou General Hospital /ID# 272735
Thessaloniki, , Greece
General Hospital Of Thessaloniki G. Papanikolaou /ID# 275323
Thessaloniki, , Greece
Tel Aviv Sourasky Medical Center /ID# 271615
Tel Aviv, Tel Aviv, Israel
Hadassah Medical Center-Hebrew University /ID# 271616
Jerusalem, , Israel
Rabin Medical Center. /ID# 271614
Petah Tikva, , Israel
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 274215
Naples, Napoli, Italy
Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 274572
Rome, Roma, Italy
I.R.C.C.S Istituto Tumori Giovanni Paolo II /ID# 274217
Bari, , Italy
Ospedale La Maddalena /ID# 274411
Palermo, , Italy
Hematologica Alta Especialidad /ID# 275279
Huixquilucan de Degollado, , Mexico
Unidade Local de Saude de Coimbra, EPE /ID# 272720
Coimbra, , Portugal
Unidade Local de Saúde Trás-os-Montes e Alto Douro /ID# 275404
Vila Real, , Portugal
Complejo Hospitalario Universitario A Coruña /ID# 272040
A Coruña, A Coruna, Spain
Institut Català d'Oncologia (ICO) - Badalona /ID# 272043
Badalona, Barcelona, Spain
Hospital Universitari Parc Tauli /ID# 272044
Sabadell, Barcelona, Spain
Hospital Universitario Reina Sofia /ID# 272051
Córdoba, Cordoba, Spain
Hospital Costa del Sol /ID# 272431
Marbella, Malaga, Spain
Hospital Universitario de Navarra /ID# 272041
Pamplona, Navarre, Spain
Hospital Universitario de Valme /ID# 272050
Seville, Sevilla, Spain
Hospital de Manises /ID# 272046
Manises, Valencia, Spain
Hospital Universitario De Burgos /ID# 272066
Burgos, , Spain
Hospital General Universitario Morales Meseguer /ID# 272466
Murcia, , Spain
Hospital Universitario Nuestra Señora de Candelaria /ID# 272413
Santa Cruz de Tenerife, , Spain
Hospital Clinico Universitario de Valladolid /ID# 272042
Valladolid, , Spain
Milton Keynes Hospital /ID# 272817
Milton Keynes, Buckinghamshire, United Kingdom
Royal Cornwall Hospital /ID# 272747
Truro, Cornwall, United Kingdom
Cheltenham General Hospital /ID# 272746
Cheltenham, Gloucestershire, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 272748
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site Coordinator
Role: primary
Site Coordinator
Role: primary
Site Coordinator
Role: primary
Site Coordinator
Role: primary
Site Coordinator
Role: primary
Site Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P24-903
Identifier Type: -
Identifier Source: org_study_id